Depressive disorders account for up to 80% of all psychiatric admissions in general. [1, 2] Individuals affected by depression are hospitalizations, and play a role in a substantial portion of hospital more likely to experience co-morbidity with other medical condi-tions. [3] Furthermore, depression is reported to increase the risk for In addition, the STAR*D team joined forces with several teams suicide attempts and suicidal ideation at least 4-to 6-fold. [4] In of geneticists. While the approaches have varied, the goal of every addition to the personal cost for the affected individuals, which is team has been the identification of genetic markers of treatment often devastating, the total cost to society is immense. Identificaoutcome, including both remission and adverse events. Results tion of disease-causing factors, along with new and more efficient from these efforts have been published in several reports and are treatment options, are therefore highly relevant.
summarized in this review.
Heritable factors have consistently been shown to play an 1. Background important role in susceptibility to depressive disorders (for a review see Levinson [5] ), but little data exist regarding the heritability of treatment response or adverse effects of medication. So far,
Depression
few genetic predictors of treatment response or adverse events have been identified, and fewer still have been replicated consistAccording to the World Health Organization (WHO), major ently (for a review see Jones and Perlis [6] ).
depression is one of the most disabling diseases worldwide. [14] It is Over the past decades there has been an impressive increase in predicted to be the second most disabling disease worldwide by the availability of treatment options; a number of psychotherapies the year of 2020. [15] [16] [17] The lifetime prevalence, according to these (talk therapies, behavior therapies) and pharmacologic agents are reports, is estimated to be 16-20%, the highest prevalence among now available to treat depression. [7, 8] However, today's treatments the psychiatric diseases. [18, 19] Women are 1.5-3.0 times more are not curative. Clinical observations have shown that a substanlikely to be affected than men, [19, 20] and major depressive disorder tial proportion of depressed patients will fail to respond to the firstis more prevalent in younger people [21] and among those with other line antidepressant treatment. Often, a second choice of treatment psychiatric disorders. [22] or addition of a second agent (augmentation) is needed to achieve There is a wealth of studies that have addressed the course of response, and full remission of symptoms can be difficult to the disease, all varying between short-and long-term follow-up achieve quickly. [7, [9] [10] [11] Although most patients will eventually reperiods. The results give a fairly consistent picture of a recurrent cover from the index episode, they often need a lifetime course of disorder with an average of one depressive episode every 5 treatment to prevent recurrence. In addition, some reports raise the years, [23, 24] but as many as 30% of patients may experience a question of whether antidepressants actually increase suicidal chronic course. [23, 25] thinking or behavior in some patients. [12, 13] Randomized clinical trials have consistently shown that most of In light of all this, clinicians encounter a very difficult task the antidepressants available on the market are more effective than when treating patients with depressive disorders. Which initial placebo, at least when treating the more severe forms of deprestreatment should be used? If this fails, what is the next best choice? sion in adults. [26] [27] [28] Nevertheless, a substantial minority of patients Is there a need for combination therapy? Which dosage and (about 20-40%, depending on initial severity) show a placebo duration of treatment should be used for achievement of full response. Recent studies [28] [29] [30] [31] have drawn a distinction between functional recovery, while minimizing adverse events? [7, 10] Exresponse (usually measured as >50% improvement from baseline), isting clinical data provide few answers, leading most clinicians to where patients can still be quite impaired by their symptoms, and employ a trial-and-error strategy, albeit enhanced by their own remission, where symptoms have essentially gone and there is no clinical judgment. Genetic tests that help guide treatment deciresidual impairment. Remission rates are lower than response rates sions would be a great advance.
for both active drug and placebo, but sustained remission of moderate or severe depression is rare with placebo alone. [28] [29] [30] [31] The general aim of the Sequenced Treatment Alternatives to When treating depressive disorders, response without remission is Relieve Depression (STAR*D) study was to help the clinician associated with continuing disability and early relapse. [32, 33] with such difficult treatment decisions by elucidating which treatment options offer the greatest efficacy and tolerability. An imporSome reports favor particular types of antidepressants [30] tant aim of the study was to identify alternative treatment stratewhereas other reports find only marginal differences. [26] Certain gies for the estimated two-thirds of patients with major depression forms of psychotherapy may compare favorably with pharmacowho do not achieve full remission after the initial treatment.
logical treatment, especially in less severe cases. [29] ApproximatePriority was given to the identification of individual patient charly one-third of patients achieve full remission when treated with acteristics related to successful treatment outcomes in real-world antidepressants; while many others will continue to experience clinical situations.
ongoing symptoms and considerable levels of disability.
We clearly need new treatment strategies that maximize remispletion of the Human Genome Project, is still a matter of desion.
bate. [49, 50] In the pharmacotherapy of psychiatric patients, clinicians have to try to help the substantial proportion of patients who do not
Suicide and Suicidal Ideation
respond sufficiently or experience adverse effects during treatment. Of course, variable response and adverse effects may be Depression has remained the main psychiatric disorder assoexplained by genetic variability in pharmacodynamic and pharmaciated with suicide, at least from the 1960s through to cokinetic pathways, but also by many other nongenetic factors, 1999-2003. [34, 35] Suicide remains a leading cause of death among including the misclassification of disease or subtype, cultural young people, [36] and one of the major causes of death among forces, or environmental factors. [51, 52] patients with mood disorders in all age groups. [37, 38] Effective Pharmacogenetics holds great promise for future clinical practreatment of depressive disorders is the best way to prevent suitice to use genetic markers for the prediction of treatment outcide. Paradoxically, antidepressant treatment may also provoke (or come. [51, 53, 54] Numerous studies have been carried out in the field, exacerbate) suicidal thoughts and behavior, especially during the but sample sizes for most studies have so far been fairly small. early phase of treatment in young people. [12, 13, 39] Concern about Association findings in the field have recently been reviewed in treatment-emergent suicidal ideation led the US FDA to issue detail by others. [55] black-box warnings [40] of the risk of suicidal thoughts and behavIt is hoped that pharmacogenetics will lead to the development ior in adolescents and young adults treated with antidepressants.
of 'personalized medicine', with better safety and efficacy than is However, doubts have persisted as to whether antidepressants currently possible for many drugs. [48, 56, 57] are a real risk factor for suicide, even in certain subgroups of But many challenges remain. How can adequate sample sizes patients. [41] [42] [43] Some studies report a protection from suicidal thinkbe collected for study? What is the best way to establish robust ing with the use of antidepressants. [44] Not all studies have taken findings? Which pharmacogenetic markers will have the greatest into account the previous history of suicidal behavior [41] and many clinical utility? How can robust, clinically useful markers be studies rely on meta-analyses with a mixed origin of the underlytranslated most efficiently to clinical use? ing data. There are important distinctions between attempts, ideation and thoughts of suicide, and actual death by suicide, [45] but many studies fail to discriminate clearly among these.
The Sequenced Treatment Alternatives to Relieve
A genetic test able to predict which patients will go on to Depression (STAR*D) Study develop suicidal thinking during antidepressant treatment would be a great aid for the clinician: those at risk could be put into As part of a larger initiative aimed at promoting large scale, special treatment regimens, and the vast majority of remaining non-industry funded clinical trials, the National Institutes of patients would not be wrongfully advised against using the antideHealth awarded a multi-million dollar contract to the STAR*D pressant. However, it is not clear what role, if any, genes might Consortium (led by Dr A.J. Rush at the University of Texas play in the etiology of treatment-emergent suicidal ideation. FamiSouthwestern Medical Center in Dallas) to study the optimal ly and twin studies certainly demonstrate that suicidal thoughts treatment strategy for major depression in outpatients. The resultand behavior that occur outside of the context of antidepressants ing STAR*D study included over 4000 outpatients with nonare both familial and heritable, [45] [46] [47] but no data exist as to the psychotic DSM-IV major depressive disorder, aged between 18 heritability of treatment-emergent suicidal thoughts or behavior, and 75 years, treated at 14 regional psychiatric and primary care and such data would be nearly impossible to obtain. clinics across the US over a period of 7 years. [58, 59] STAR*D is by far the largest study of its kind to date. Ascertainment was aimed at enrolling a representative sample
The Pharmacogenetic Approach
of outpatients with a typical mix of race, ethnicity, and socioecoToday, 'pharmacogenetics' refers to the study of individual nomic status. There were few exclusion criteria, and adjunctive differences in drug response related to genetic variation among treatment with benzodiazepines and hypnotics was allowed when individuals, whereas the term 'pharmacogenomics' tends to emneeded. All participants received active treatment, since placebo phasize the technologies used in the development of new drugs randomization tends to select for an unrepresentative subset of based on the knowledge of all genes in the human genome. [48] In mildly depressed patients. Many study participants were indeed practice, the two terms are often used interchangeably. Whether quite ill: 75% had experienced two or more prior episodes, or a pharmacogenetics is an old discipline or was born after the comsustained episode, of depression during the 2 years prior to study entry, and two-thirds reported co-morbidity with another psychiatfor involvement of the HTR2A gene in antidepressant outcome, no ric disorder. [60] direct replication of results from previous studies could be established. Treatment was organized into 'levels', each with a limited number of treatment options offered for up to 12 weeks. ParticiThe associated marker, rs7997012 (HTR2A IVS2 A/G), had a pants who responded well moved into follow-up; the others had modest effect on treatment outcome in the STAR*D sample. the option to move on to the next level of treatment. All particiPatients homozygous for the better outcome-associated 'A' allele pants began in Level 1 with citalopram 10-60 mg/day, as tolerathad an 18% lower absolute risk of nonresponse compared with ed, for up to 12 weeks. Citalopram is a typical selective serotonin those homozygous for the other allele. [61] The marker resides reuptake inhibitor (SSRI).
within the second intron of HTR2A, and has no clear functional In order to enable future pharmacogenetic studies, STAR*D consequences. This finding now awaits replication in an indepenparticipants were asked to donate a blood sample for DNA extracdent sample and functional characterization. tion. About half agreed, and blood samples were drawn from close Interestingly, it was found that the frequency of the outcometo 2000 participants. These samples are now available to researchassociated variant was lower in self-described 'Black' patients ers through the Rutgers University Cell and DNA Repository in compared with 'White' patients. The clinical STAR*D study had Piscataway, New Jersey, USA (http://www.rucdr.org/).
shown a poorer response of Black participants to the citalopram STAR*D is the largest pharmacogenetic study of mood disortreatment, which was largely related to socioeconomic differders carried out to date. It has provided, and continues to provide, a ences. [68, 69] This finding highlights one of the problems with a tremendous opportunity to elucidate genetic determinants of treatracially and ethnically mixed group of patients: any polymorphism ment outcome. Some of the published pharmacogenetic findings that shows a large difference in frequency between populations from the first level of treatment will be described below.
will show association with treatment response if such response differs greatly between these populations. In order to exclude that 2. Results from Candidate Gene Studies the observed association with citalopram treatment was an artifact induced by such stratification, McMahon et al. [61] tested association in White patients only, which still remained highly signif-
Treatment Response and Remission
icant. This indicates that it is unlikely that the observed association
HTR2A and GRIK4
was an artifact caused by the inclusion of participants of mixed racial and ethnic backgrounds. Since the number of Black patients One large-scale candidate gene association study of the carrying the outcome-associated allele was very small, it was not STAR*D sample was aimed at investigating the outcome phenopossible to determine how much of the racial difference in outtypes 'remission' and 'response'. 'Response' refers to improvecome was attributable to race per se. ment in depressive symptoms, while 'remission' refers to complete or nearly complete recovery (for details regarding the experiThe second marker significantly associated with antidepressant mental design, see McMahon et al. [61] ). A split-sample design was outcome in the STAR*D sample was located in the GRIK4 gene, utilized in order to address the multiple testing problem (subsecoding for a kainic-acid type glutamate receptor. [63] The C allele of quent work suggested alternative approaches to this problem [62] ).
the marker rs1954787 (a C/T SNP in the first intron of the GRIK4 This first study included 68 genes, based on known gene gene) was associated with better outcome. The effect was modest, function or previously reported involvement in depressive disorder but homozygote carriers of the outcome-associated marker alleles or treatment outcome. Accordingly, after stringent criteria, 768 of both GRIK4 and HTR2A were about half as likely to experience genetic markers (single nucleotide polymorphisms; SNPs) were non-response to treatment with citalopram as those who did not selected. Results from the primary analysis have been published in carry any of these alleles ( figure 1 ). This finding was the first two reports. [61, 63] Two markers showed significant association that direct human evidence that the glutamate system plays an imporwas reproduced in both split samples: one marker was located in tant role in response to an antidepressant. Glutamate signaling and the gene HTR2A and one was located in the gene GRIK4.
post-synaptic serotonin (5-hydroxytryptamine; 5-HT) signaling HTR2A codes for the type 2A serotonin receptor, which has are known to interact via the post-synaptic complex PPP1R1B been implicated in a large number of association studies in schizo-(protein phosphatase 1, regulatory subunit 1B; formally known as phrenia, depression, and treatment response. [64] However, the DARPP-32) [reviewed in Svenningsson et al. [70] ], so the additive markers that showed association in the McMahon et al. [61] study effects of HTR2A and GRIK4 on treatment outcome may work via were different from, and uncorrelated with, those previously imthis pathway. GRIK4 had previously been implicated in a transloplicated. [65] [66] [67] Thus, although this study provides further evidence cation event in a patient with schizophrenia, [71] and the marker and Gutknecht [75] ). Nakamura and collaborators [76] have argued that a single nucleotide variant (A>G) within the HTTLPR should be considered when evaluating 5-HTT function. Subsequent functional studies of these variants on mRNA levels of the 5-HTT have also shown the importance of the single base mutation (G) in the long allele. The LG polymorphism was associated with a decrease of function almost equivalent to S-allele carriers.
[77]
The HTTLPR has been reported to be associated with a large number of psychiatric and behavioral phenotypes. These include the personality trait of novelty seeking, [78] various measures of depression and anxiety, [79] depression that follows adverse life events, [80] and lifetime risk of major depression. [81] The S allele is often -but not always -more common in individuals with these personality traits or disorders.
A number of pharmacogenetic studies have assessed whether genetic variants in SLC6A4 could predict antidepressant-treatment outcome. These studies are quite heterogeneous with regard to study design, sample characteristics, ethnicity, and intervention strategies (reviewed by Smits et al. [82] ), which complicates an overall interpretation of the results. For example, people of Asian origin differ in HTTLPR allele frequencies. [83] Previous literature identified in STAR*D had been associated with schizophrenia in suggests that the SLC6A4 HTTLPR S/S genotype may be assoanother sample. [71] This suggests that GRIK4 may contain variants ciated with risk of depression and reduced response to SSRI involved in several psychiatric traits. Large samples will likely be treatment. needed for replication testing. [72] 5-HTT was also studied in the primary outcome candidate gene study of STAR*D. A dense set of SNP markers spanning the
The Serotonin Transporter Gene (SLC6A4)
SLC6A4 coding region were genotyped. However, no significant The development of SSRIs as antidepressant drugs has mainly association with treatment outcome was seen. [61] The HTTLPR been based on knowledge gathered during the use of first-and was investigated directly in a second study of the STAR*D samsecond-line antidepressant medications (tricyclics and monoamine ple. [84] No association was detected between treatment outcome oxidase inhibitors). All of these regulate concentrations of several and the L/S alleles of the HTTLPR. There was also no significant synaptic monoamines unselectively. The SSRIs were designed to association with treatment outcome when the HTTLPR was treatblock the reuptake of serotonin from the synapse by the serotonin ed as a tri-allelic polymorphism, based on the SNP noted above. transporter. SSRIs quickly became the most widely prescribed However, a significant association of the tri-allelic polymorphism antidepressants in Western countries, mainly because of their wide with overall adverse effect burden was observed. This is consistent acceptability, with fewer adverse effects and greater drug safety.
with an earlier study that detected a strong association between the Since all SSRIs bind to the serotonin transporter, the gene encod-S allele and SSRI adverse effects in a geriatric sample. [85] It is ing this protein has become an obvious candidate for possible that an association between the HTTLPR and SSRI pharmacogenetic studies in depression.
adverse effects may have influenced other, smaller The 5-HT transporter (5-HTT) gene SLC6A4 is modulated by a pharmacogenetic studies that did not account for drug tolerability, functional polymorphic promoter region, known as the 'linked since medication-intolerant patients would be able to tolerate only polymorphic region' (HTTLPR), which is located upstream of the a low dose, and may be under-medicated. transcription start site. This polymorphism consists of a complex Despite the rather exhaustive investigation of 5-HTT in the repeat polymorphism with many alleles, which are typically STAR*D study, there was no evidence of a role in treatment grouped into short (S) and long (L) allele sets. [73] outcome. This shows that even an obvious candidate gene coding In vitro studies in human cell lines have shown that the HTfor the drug target itself and previously implicated in treatment TLPR is associated with changes in 5-HTT translation.
[74] L alleles response can render negative results in a well powered sample. It produce higher levels of 5-HTT mRNA (for a review see Lesch remains to be seen whether the association between 5-HTT and adverse effects observed in STAR*D will prove more robust than ized patients with unipolar and bipolar disorders. The 'Winner's that with treatment outcome.
Curse' also predicts that the initial study reporting an association often over-estimates effect sizes. [103, 104] 
FKBP5
Further studies are needed, but these findings appear to constitute an independently replicated association between a functional Homeostatic response to stress is strongly influenced by the genetic polymorphism and antidepressant treatment outcome. The hypothalamic-pituitary-adrenal (HPA) axis. [86, 87] Agents such as relative importance of this association in predicting treatment adrenocorticotrophin (ACTH), arginine vasopressin (AVP), and outcome prospectively remains to be determined. corticotropin-releasing hormone (CRH) appear to have important stress-regulatory functions as well. [88] Abnormalities in HPA-axis
Other Studies function have been reliably detected in stress-related disorders and
Other genetic studies of the STAR*D sample, recently pubit has been proposed that dysregulation in this neuroendocrine lished, await replication in the literature. Perlis and collaboraaxis, mainly by altered secretion of cortisol, is a major mechanism tors [105] studied four candidate genes whose murine analogs apfor developing depressive disorders. [89, 90] This has led to the peared to be involved in antidepressant treatment response. None hypothesis that drugs that target the HPA axis may be beneficial of the markers in any of the genes were associated with outcome at for treating depressive disorders. [91, 92] Such drugs might normalize Level 1 after correction for multiple testing. However, among 751 cortisol levels or modulate glucocorticoid receptor (GR) func-STAR*D participants who entered Level 2, there was a significant tion. [91, 93] association between outcome and 3 of 4 markers in the gene Animal studies suggest that the GR acts as a prominent regula-TREK1. This gene encodes a potassium channel and has been tor of the HPA axis. [94] [95] [96] Furthermore, some genetic studies have shown to be an important target for antidepressant drugs in mouse found that polymorphisms in the NR3C1 (GR) gene may be models. [106, 107] associated with susceptibility to depression, [97, 98] as well as treatPeters et al.
[108] studied 15 genetic polymorphisms in five ment response. [97] cytochrome P450 (CYP) genes that have been widely studied in A possible involvement of GR function in HPA-axis regulation pharmacogenetics. No genetic polymorphism was significantly and depression and response to antidepressant treatment was studassociated with either response or tolerance phenotypes. These ied by Binder and collaborators. [99] No association with depression data were consistent with a recent meta-analysis that found CYP was observed for markers in the NR3C1, AVP, CRH genes or five testing of no clinical utility in the routine treatment of major chaperones (BAG1, STUB1, TEBP, FKBP4, and FKBP5) of the depression with SSRIs.
[109]
GR, in hospitalized patients of European ancestry diagnosed with major depression. However, a highly significant association was
Treatment-Emergent Suicidal Ideation
observed between treatment response and a marker located in FKBP5, which encodes one of the chaperone molecules. The
GRIK2 and GRIA3
response phenotype was associated with the homozygous state of Laje et al. [110] used a candidate-gene approach in the same 68 the T allele of the functional polymorphism rs1360780 (FKBP5 candidate genes that were investigated in the primary outcome IVS2 C/T). These same individuals had also experienced more analysis (see above). [61, 63] They defined treatment-emergent suilifetime episodes of depression.
cidal ideation as the absence of suicidal thoughts at the first Small studies did not replicate these findings in outpatients of clinical visit followed by onset of suicidal thoughts at any later Chinese ancestry, [100] or in an independent European sample. [101] visit during the 12 weeks of Level 1. By this case definition, 120 However, these non-replications could be due to the low power of patients were considered to display treatment-emergent suicidal small sample sizes. Therefore, the large STAR*D cohort constitutideation, although the majority of these reported only passive ed an excellent opportunity to investigate the association of markdeath wishes. The rest of the sample reported suicidal thoughts at ers in the FKBP5 gene.
baseline or denied suicidal thoughts throughout Level 1, and were treated as 'controls' (n = 1742). The results in the STAR*D cohort [102] supported an association between markers in the FKBP5 gene and disease status as well as
The analysis revealed two markers that, after correction for antidepressant treatment outcome. However, no association with multiple testing, were significantly associated with treatmentthe number of prior lifetime depressive episodes was detected. emergent suicidal ideation. The markers resided in the ionotrophic Effect sizes were clearly smaller than those reported by Binder et glutamate receptor genes GRIK2 and GRIA3. Both markers reside al. [99] This may reflect differences in the samples, as the STAR*D within introns and have no obvious functional significance. The enrolled outpatients with unipolar depression rather than hospital-GRIK2 marker rs2818224 conferred a rather high odds ratio (OR) of about 8 in the homozygous state, but this genotype was uncommany specific multi-allele combinations will need to be considmon (12%). The G allele of marker rs4825476 (in the third intron ered. The numbers of patients who carry any particular multi-allele of the GRIA3 gene), while more common, was associated with combination will thus be necessarily low, leading to a test with low increased risk, conferring an OR of 1.9. This was the first study to sensitivity. On the other hand, if there is strong heterogeneity of demonstrate a significant, overall association between treatmenteffects, with some alleles being important in only some populaemergent suicidal ideation and genetic markers, although a study tions, then test specificity may prove a problem. published earlier that same year found suggestive evidence of an association with alleles in another gene -CREB1 -in males. [111, 112] 4. Future Directions: Moving Pharmacogenetics Although these findings have evoked substantial interest in the Findings from the Bench to the Bedside scientific community and media, [113] a clinically useful genetic test for treatment-emergent suicidal ideation does not seem to be
There is a sense of urgency to use pharmacogenetic information imminent. Replication in an independent sample is the essential to inform treatment decisions. [118] Patients might benefit from next step; independent replication will not only verify true-posibeing matched with medications to which they are likely to restive associations, but also give a better estimation of the true effect pond well without serious adverse effects. Healthcare systems size, free of the Winner's Curse. If such a test should emerge in the might benefit from more efficient treatment selection and consefuture, it might offer a useful tool for clinicians who wish to quently the more rapid recovery of patients. Society might benefit identify patients in need of closer monitoring or alternative treatfrom decreased costs related to reduced healthcare utilization, ments.
recouped productivity by more treatment-responsive patients, and decreased use of unnecessary expensive treatments and polypharmacy.
Discussion
However, a too-rapid movement from laboratory to clinic poses significant risks. Poorly validated tests might actually mislead We have reviewed some of the early pharmacogenetic findings physicians into prescribing less than optimal treatments. [119] Inadefrom the STAR*D trial. Some previously well established findings quate data on the range of appropriate treatment contexts and were not supported, such as the association between SLC6A4 and target populations may lead to the misapplication of particular treatment outcome, but several previous association findings retests, reducing their value in clinical decision making. Even valid ceived direct (FKBP5) or indirect (HTR2A) support. Several novel tests, properly used, may not really affect the choice of treatments findings also emerged, which will need to be tested in independent or dosages, especially when treatment alternatives are limited or samples. So far we have examined only a small fraction of the other clinical factors take precedence. The recent report of The known common genetic variation and possible outcome phenoEvaluation of Genomic Applications in Practice and Prevention types and adverse events. Outcomes and adverse events in treat-(EGAPP) Working Group is a good example: although CYP ment levels beyond Level 1 remain to be studied, although sample polymorphisms can be reliably genotyped and are associated with sizes fall rapidly as patients move through the levels. Genomeblood levels of many SSRIs, CYP genotyping was found to have wide association studies in the STAR*D cohort may provide little clinical impact and no real utility in clinical decision making further answers.
for patients with typical major depressive disorder.
As seen so often in the field of complex genetics, we learn from In light of these issues, a consensus seems to be emerging that the STAR*D pharmacogenetic approach that having a large samproposed pharmacogenetic tests should be required to meet some ple is good, but having an even larger sample is better. Most of the criteria before widespread clinical application is warranted. Criteeffect sizes detected in the STAR*D genetics studies so far are ria under discussion include: [109] small -and the only large effect (GRIK2 and treatment-emergent 1. Analytic validity: is the genetic test to be used an accurate suicidal ideation) was seen for an uncommon genotype. Thus, very reflection of the underlying DNA sequence? large samples will be needed in order to test these findings for 2. Clinical validity: is the genetic marker reliably (reproducibly) replication in other samples. Recent successful replication studies associated with the outcome? Is the reported sensitivity and speciin type 2 diabetes mellitus [114] [115] [116] [117] have demonstrated the value of ficity valid in the targeted clinical population? very large sample sizes, probably with an order of magnitude larger than what was available in the STAR*D cohort.
3. Clinical utility: will the results of the test actually affect clinical decision making in a way that improves patient outcomes? Clinical tests will likely require information from a panel of many genetic markers, the majority of which still remain to be Analytical validity is relatively easy to establish in this era of identified. If there are strong interactions among the markers, then high-throughput genomic technologies, but should not be taken for 
